[Treatment of essential tremor].
Marchand
L
L
CSPQ, FRCP, Université de Montréal.
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008704:Methazolamide / Q000627:therapeutic use; D009553:Nimodipine / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy; D010634:Phenobarbital / Q000627:therapeutic use; D011324:Primidone / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use*; D013565:Sympatholytics / Q000627:therapeutic use*; D013788:Thalamus / Q000601:surgery; D014202:Tremor / Q000188:drug therapy* / Q000601:surgery; D014665:Vasodilator Agents / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D018726:Anti-Dyskinesia Agents; D006993:Hypnotics and Sedatives; D013565:Sympatholytics; D014665:Vasodilator Agents; D011324:Primidone; D009553:Nimodipine; D011433:Propranolol; D001905:Botulinum Toxins; D008704:Methazolamide; D010634:Phenobarbital
Le traitement du tremblement essentiel.